Bloch Stephen M sold $26.6M of LQDA (indirect holdings)

Bloch Stephen M sold 388,223 indirectly-held shares of Liquidia Corp (LQDA) at an average of $68.61 ($64.48–$72.41, $26.63M total) across 10 trades over 2026-06-10 to 2026-06-11.

Original reporting
SEC EDGAR · Bloch Stephen M
Published Jun 12, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The disclosure can influence short-term sentiment and positioning, but it does not provide new information about Liquidia’s pipeline, financial results, or regulatory status.

02

Market read

A director sold ~$26.6M of LQDA stock across 10 trades at prices ranging from ~$64.48 to ~$72.41.

03

What to watch

The filing notes indirect ownership and that a pre-arranged 10b5-1 plan was not used; traders may over-interpret intent without additional context (taxes, diversification, estate planning).

Relevance 7/10Novelty 8/10Timing: today’s SEC Form 4 filing (filed 2026-06-12)

Background

The article reports an SEC Form 4 insider transaction for Liquidia Corp, detailing a director’s open-market sale of shares.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

Liquidia Corp director Stephen M. Bloch sold $26.63M of LQDA shares via open-market transactions (Form 4, indirect holdings).

Expected impact

Likely modest downward pressure or increased caution around LQDA, with limited follow-through unless additional company-specific news emerges.

Evidence & confidence

The article is a primary SEC Form 4 disclosure of a large sale ($26.6M) by a director, but it does not indicate why the sale occurred (no 10b5-1 plan stated) or any new operating/regulatory development.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Large insider sales can be routine liquidity/portfolio rebalancing and may not reflect deteriorating fundamentals, especially when trades are spread across multiple days.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider sale disclosure.

  • Stephen M. Bloch

    Director who sold 388,223 shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.